21 May 2026
Eris Lifescience guides FY27 revenue growth at 18% to 20%.
This is well ahead of India's pharma industry average of 9 to 10%, driven by chronic therapy launches and integration gains from the Biocon Biologics asset acquisition.
Every Finvezto stock note on Eris Lifesciences, dated and newest first. Coverage spans pharma.
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630. Stock notes are market commentary for general information and education. They are not investment advice, not a recommendation to buy or sell, and do not account for any individual's financial situation. Investment in securities is subject to market risks. Please read all related documents carefully before investing. Past performance is not a guarantee of future results.